Bristol-Myers Squibb (NY:BMY)

Eli Lilly Solidifies Immunology Dominance with $1.2 Billion Acquisition of Ventyx Biosciences

Topics Artificial Intelligence Intellectual Property

January 09, 2026

In a move that underscores the tightening intersection between metabolic health and systemic inflammation, Eli Lilly and Company (NYSE: LLY) officially announced on January 7, 2026, its definitive...

J&J Cuts Deal With Trump’s White House To Slash Drug Prices And Dodge Tariffs ↗

January 08, 2026

The $20 Billion Question: Revolution Medicines Surges as Big Pharma Circles the Pan-RAS Leader

Topics Government

January 08, 2026

The first week of 2026 has set the biotech sector ablaze, with Revolution Medicines (NASDAQ: RVMD) finding itself at the epicenter of a high-stakes acquisition tug-of-war. Shares of the Redwood...

As the pharmaceutical industry rings in 2026, the landscape of healthcare investment has shifted from cautious recovery to a full-scale acquisition frenzy. Driven by a looming "super-cliff" of patent...

Topics Intellectual Property

The 2026 Pharma M&A Outlook: Obesity, HIV, and the Biotech Renaissance

January 07, 2026

The big news in the drug sector is the emergence of GLP-1 weight loss drugs, but dig deeper, and you'll find relatively cheap industry giants to consider.

Topics Artificial Intelligence Economy Intellectual Property

3 Drug Stocks to Buy at a Discount ↗

January 07, 2026

The 2026 Pharma Reset: How Industry Giants Are Navigating a New Era of Federal Price Controls

Discover which S&P500 stocks are making waves on Wednesday. ↗

January 07, 2026

Via Chartmill

January 02, 2026

Yesterday marked the official commencement of the first-ever "Maximum Fair Prices" (MFPs) for ten of the most widely used drugs in the Medicare program, a direct result of the Inflation Reduction Act’s...

This ETF could produce robust total returns in 2026 and beyond.

Topics Economy Intellectual Property World Trade

1 Top ETF I Plan to Load Up on in 2026 ↗

January 02, 2026

Pfizer’s Dividend Trap or Deep Value? Analyzing the Pharma Giant as Shares Languish Below $30

Topics ETFs Stocks

January 01, 2026

As the calendar turns to January 1, 2026, Pfizer Inc. (NYSE: PFE) finds itself in a position that would have been unthinkable during the height of the pandemic. Once the darling of the pharmaceutical...

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, which has supported the...

Topics Intellectual Property

2 Healthcare Stocks for Long-Term Investors and 1 We Find Risky

December 31, 2025

Via StockStory

Topics Stocks

The Metabolic Squeeze: Big Pharma’s 2025 Defined by $1 Trillion Valuations and Regulatory Reckonings

December 31, 2025

As 2025 draws to a close, the pharmaceutical industry stands at a historic crossroads. The year was defined by a widening chasm between the "metabolic haves"—those profiting from the global obesity...

As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the...

Topics Economy Intellectual Property Law Enforcement

Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026

December 31, 2025

These stocks can be great sources of portfolio growth in the years ahead.

Topics Artificial Intelligence ETFs Economy

2 Dividend Stocks to Scoop Up Without Hesitation Right Now ↗

December 31, 2025

The stock has been on the rebound for several months, but can it keep the momentum going?

Topics Bankruptcy Initial Public Offering

Is Bristol Myers Squibb a Buy, Sell, or Hold in 2026? ↗

December 30, 2025

As the sun sets on 2025, investors are increasingly pivoting toward the pharmaceutical sector, seeking a "defensive income fortress" to weather potential macroeconomic volatility in 2026. The...

Topics Intellectual Property

The 2026 Income Fortress: Why Big Pharma is the Defensive Play of the New Year

December 30, 2025

Investors seeking reliable dividends will find that this trio of healthcare stocks offers an exciting combination of safety, growth, and income.

Topics Artificial Intelligence Economy Intellectual Property

Got $500? 3 Dividend-Paying Healthcare Stocks to Buy and Hold Forever ↗

December 30, 2025

The GLP-1 fight just entered a new round, and it highlights why these three out-of-favor drug makers are worth a deep dive.

Topics Economy Intellectual Property

3 Drug Stocks to Buy at a Discount ↗

December 27, 2025

If you are looking for high yields, this drug maker and this device maker are both worth a deep dive today.

Topics Intellectual Property

Got $1,000? 2 High-Yield Healthcare Stocks to Buy and Hold Forever ↗

December 24, 2025

Bristol Myers Squibb Co (NYSE:BMY) Presents a Classic Value Investing Case Amid Transition ↗

Topics Intellectual Property

December 24, 2025

Bristol Myers Squibb (BMY) presents a classic value investing case, trading at a significant discount with strong profitability and a high dividend yield, despite near-term patent challenges.

Via Chartmill

Topics Intellectual Property

Dividend Stocks Are the Gift that Will Keep On Giving You More Income in 2026 ↗

December 24, 2025

These dividend investments can provide you with a growing income stream in 2026.

Fitch Sees Stable 2026 Outlook For Global Pharma — But Warns Trump Drug Pricing Push Poses Profit Risk ↗

Topics Economy

December 23, 2025

The Next Big Buyout? Abivax Emerges as a Premier M&A Contender for 2026 Amidst Biotech Consolidation Wave

Topics Government

December 23, 2025

As the biotech sector closes out a transformative 2025, one name has risen to the top of every institutional investor's watchlist: Abivax (NASDAQ: ABVX). Following a year of stellar clinical results...

After a tumultuous first half of 2025 that saw the pharmaceutical and biotechnology sectors languish under a cloud of regulatory dread, the industry is ending the year on a surprisingly high note. The...

Topics Intellectual Property

The Great Biotech Rebound: How Pricing Clarity Rescued the Drug Sector in 2025

December 23, 2025

Even if you think the market will slump, selling your holdings isn't an ideal strategy.

Topics Economy

Should Retirees Pull Their Money Out of the Stock Market in 2026? ↗

December 21, 2025

Bristol-Myers Squibb Co (NYSE:BMY) Offers a High-Quality Dividend Profile for Income Investors ↗

Topics ETFs Economy Retirement

December 20, 2025

Bristol-Myers Squibb (BMY) offers a high 4.92% dividend yield with a strong growth history, backed by solid earnings and a satisfactory financial condition for income investors.

Via Chartmill

Trump Strikes New Drug-Price Deals With Roche, Novartis, Merck And Other Pharma Giants ↗

December 19, 2025

The deals expand the pricing program to most targeted drugmakers in exchange for temporary tariff relief.

This Is the 2nd Priciest Stock Market in 155 Years, Which Makes This High-Yield ETF a Genius Buy for 2026 ↗

Topics Government World Trade

December 19, 2025

This top-shelf exchange-traded fund (ETF) checks all the right boxes for income- and value-seeking investors.

The healthcare industry has never been a great source of dividends -- that alone makes these companies exceptional.

Topics Artificial Intelligence ETFs Economy

These 2 Healthcare Stocks Just Declared Dividend Raises ↗

December 17, 2025

Novartis US Stock Rises On Reports Of White House Pricing Deal Due Friday — Roche Also In Talks ↗

Topics Intellectual Property

December 17, 2025

The potential agreements would mark another step in Washington’s broader effort to reshape drug pricing.